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What are they? Fibroblast growth
factors (FGFs) are a family of small
(20–30 kDa) intercellular signalling
proteins which are frequently
found to be glycosylated. The first
draft of the human genome
identified 29 potential FGF genes,
and so far transcripts have been
identified for 23 of them. Two
FGFs have been identified in
Caenorhabditis elegans (Let-756
and Egl-17) while Drosophila
appears only to have a single FGF
gene (branchless). The
identification of six FGF genes in
the sea squirt, Ciona, a basal
chordate, suggests that the
process of gene duplication and
divergence was well underway
early during chordate evolution.
How do they signal across the
cell membrane? Signal
transduction occurs via a family of
four transmembrane receptor
tyrosine kinases; presentation of
FGF to the receptor by a
sulphated glycosaminoglycan
(GAG) co-factor is obligatory for
receptor activation. As for other
receptor tyrosine kinases,
activation of FGF receptors
appears to be achieved by
dimerisation, although the precise
receptor:ligand:co-factor
stoichiometry remains
controversial.
What signalling cascades do
they activate? A lot. Currently, it
seems that activation of the
Ras/MAP kinase pathway
underlies many cellular responses
to FGF. This is achieved via
interaction of FRS2 adaptor
proteins with the receptor, and
direct and indirect recruitment and
activation of up to six Grb2–Sos
complexes. Further Grb2–Sos
complexes are recruited to FGF-
receptor-bound Shp-2. Grb2 also
recruits Gab1, thereby initiating
the PI 3-kinase pathway. The
inositol lipid/calcium pathway is
also activated following interaction
of phospholipase C-γ with the FGF
receptor and there is evidence for
FGF receptor interaction with
downstream components Crk,
Shc, Shb, Src and p85.
Is there feedback regulation?
Receptor activity appears to be
antagonised by transmembrane
proteins, tyrosine phosphatases
and Sef proteins, while the
Ras/MAP kinase pathway is
regulated at multiple levels. MAP
kinase phosphorylates FRS2,
preventing Grb2 binding; it also
induces MAP kinase phosphatase,
a MAP kinase antagonist, and the
Sprouty proteins that inhibit
Grb2–FRS2 interactions. Sprouty
proteins can also bind the
ubiquitin ligase Cbl, and through
this interaction they may regulate
FRS2–FGF receptor ubiquitination
and degradation.
This all sounds very complex.
Yes, and that’s not all. The RNAs
for FGF receptors 1–3 are subject
to alternative splicing which alters
their specificity for the different
ligands, and it is also clear that
ligand–receptor specificities can
be modulated according to which
GAGs present the ligands.
Alternative splicing also can
generate secreted FGF receptor
extracellular domains, which likely
function as competitive inhibitors.
Indeed, a recently identified fifth
human FGF receptor lacks all
cytoplasmic and transmembrane
sequences.
I hope that the biology of the
ligands is simpler. I’m afraid not.
The RNAs for many of these also
undergo alternative splicing that
sometimes affects receptor
specificity, and antisense
transcripts may regulate their
expression. Also, while most are
constitutively secreted, secretion
of some FGFs, including the
prototypic members FGF1 and
FGF2, appears to occur through
regulated pathways. Several FGFs
have also been found to enter the
cell nucleus, either of cells that
synthesise them or following
interaction with surface FGFRs.
Indeed, nuclear complexes
including active FGF receptor
kinase domains have been
reported but nuclear functions
remain unclear.
Okay, okay, but what do they
do? They have been implicated in
the regulation of virtually all key
cellular responses: proliferation,
apoptosis, differentiation, regional
identity, metabolic control,
movement and chemotaxis.
Clinically, they are potent
oncogenic and angiogenic
agents, while mutations in FGF
receptors underlie at least 11
syndromes. Developmentally,
FGFs are required for many
processes including mesoderm
and neural induction, limb
outgrowth, branching
morphogenesis in the lung,
regional patterning of the
developing brain, induction of the
otic placode and development of
cranial cartilage.
So do they make fibroblasts
grow and divide? Although FGFs
are mitogens for many
transformed fibroblast cell lines,
such as the ubiquitous NIH 3T3
cell, many primary fibroblasts are
unresponsive to FGFs. But then
what’s in a name?
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Figure 1. Ribbon model of FGF1 protein
showing receptor (red) and GAG (blue)
contact sites. Data from  Pellegrini et al.
(2000) Nature 407, 1029-1034. (Thanks to
Gareth Williams for generating the
image.)
